Investment Thesis
Treace Medical faces a profitability crisis with severe operating losses (-36.4% margin) despite strong gross margins (79.3%), indicating underlying operational inefficiency. Revenue growth is essentially flat (1.6% YoY) leaving no clear path to profitability, while the company carries $55.8M in debt with negative interest coverage and only $9.5M in cash.
Strengths
- Exceptional gross margin of 79.3% indicates strong core product economics and pricing power
- Positive free cash flow of $4.2M despite operating losses provides near-term runway
- Solid short-term liquidity with current ratio of 3.58x
Risks
- Severe profitability crisis with -$17.2M operating loss and -38.1% net margin showing unsustainable operational structure
- Stagnant revenue growth of 1.6% YoY provides no near-term path to profitability or earnings improvement
- High debt burden of $55.8M with negative interest coverage ratio (-10.9x) creates financial distress risk and limits strategic flexibility
- Depleting cash position relative to debt obligations and operating burn rate
Key Metrics to Watch
- Operating margin trajectory and operating expense reduction initiatives
- Revenue growth acceleration and market share trends in surgical device segment
- Cash balance depletion rate and debt covenant compliance status
- Operating cash flow sustainability given negative net income
Financial Metrics
Revenue
47.2M
Net Income
-18.0M
EPS (Diluted)
$-0.28
Free Cash Flow
4.2M
Total Assets
184.1M
Cash
9.5M
Profitability Ratios
Gross Margin
79.3%
Operating Margin
-36.4%
Net Margin
-38.1%
ROE
-23.3%
ROA
-9.8%
FCF Margin
8.9%
Balance Sheet & Liquidity
Current Ratio
3.58x
Quick Ratio
2.53x
Debt/Equity
0.72x
Debt/Assets
58.1%
Interest Coverage
-10.93x
Long-term Debt
55.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-10T07:50:25.270903 |
Data as of: 2026-03-31 |
Powered by Claude AI